Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10
Background Interleukin-15 (IL-15) promotes growth and activation of cytotoxic CD8+ T and natural killer (NK) cells. Bioactive IL-15 is produced in the body as a heterodimeric cytokine, comprising the IL-15 and IL-15 receptor alpha chains (hetIL-15). Several preclinical models support the antitumor a...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000599.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850197383929921536 |
|---|---|
| author | Bernard A Fox Cristina Bergamaschi George N Pavlakis Antonio Valentin Jenifer Bear Barbara K Felber Shawn M Jensen Hrishikesh Pandit Bethany A Nagy Dimitris Stellas Maggie Cam |
| author_facet | Bernard A Fox Cristina Bergamaschi George N Pavlakis Antonio Valentin Jenifer Bear Barbara K Felber Shawn M Jensen Hrishikesh Pandit Bethany A Nagy Dimitris Stellas Maggie Cam |
| author_sort | Bernard A Fox |
| collection | DOAJ |
| description | Background Interleukin-15 (IL-15) promotes growth and activation of cytotoxic CD8+ T and natural killer (NK) cells. Bioactive IL-15 is produced in the body as a heterodimeric cytokine, comprising the IL-15 and IL-15 receptor alpha chains (hetIL-15). Several preclinical models support the antitumor activity of hetIL-15 promoting its application in clinical trials.Methods The antitumor activity of hetIL-15 produced from mammalian cells was tested in mouse tumor models (MC38 colon carcinoma and TC-1 epithelial carcinoma). The functional diversity of the immune infiltrate and the cytokine/chemokine network within the tumor was evaluated by flow cytometry, multicolor immunohistochemistry (IHC), gene expression profiling by Nanostring Technologies, and protein analysis by electrochemiluminescence and ELISA assays.Results hetIL-15 treatment resulted in delayed primary tumor growth. Increased NK and CD8+ T cell tumoral infiltration with an increased CD8+/Treg ratio were found by flow cytometry and IHC in hetIL-15 treated animals. Intratumoral NK and CD8+ T cells showed activation features with enhanced interferon-γ (IFN-γ) production, proliferation (Ki67+), cytotoxic potential (Granzyme B+) and expression of the survival factor Bcl-2. Transcriptomics and proteomics analyses revealed complex effects on the tumor microenvironment triggered by hetIL-15 therapy, including increased levels of IFN-γ and XCL1 with intratumoral accumulation of XCR1+IRF8+CD103+ conventional type 1 dendritic cells (cDC1). Concomitantly, the production of the chemokines CXCL9 and CXCL10 by tumor-localized myeloid cells, including cDC1, was boosted by hetIL-15 in an IFN-γ-dependent manner. An increased frequency of circulating CXCR3+ NK and CD8+ T cells was found, suggesting their ability to migrate toward the tumors following the CXCL9 and CXCL10 chemokine gradient.Conclusions Our results show that hetIL-15 administration enhances T cell entry into tumors, increasing the success rate of immunotherapy interventions. Our study further supports the incorporation of hetIL-15 in tumor immunotherapy approaches to promote the development of antitumor responses by favoring effector over regulatory cells and by promoting lymphocyte and DC localization into tumors through the modification of the tumor chemokine and cytokine milieu. |
| format | Article |
| id | doaj-art-2686c70aeb584a37955fa177f72ca91d |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-2686c70aeb584a37955fa177f72ca91d2025-08-20T02:13:11ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-05-018110.1136/jitc-2020-000599Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10Bernard A Fox0Cristina Bergamaschi1George N Pavlakis2Antonio Valentin3Jenifer Bear4Barbara K Felber5Shawn M Jensen6Hrishikesh Pandit7Bethany A Nagy8Dimitris Stellas9Maggie Cam10Department of Molecular Microbiology and Immunology, Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, Oregon, USAHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USACenter for Cancer Research, National Cancer Institute, Frederick, Maryland, USA2 Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA1 Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USAHuman Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USADepartment of Molecular Microbiology and Immunology, Providence Cancer Institute, Earle A. Chiles Research Institute, Portland, Oregon, USA2 Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USA2 Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland, USANational Cancer Institute at Frederick, Frederick, MD, USA4 Office of Science and Technology Resources, Center for Cancer Research, National Cancer Institute, Frederick, Maryland, USABackground Interleukin-15 (IL-15) promotes growth and activation of cytotoxic CD8+ T and natural killer (NK) cells. Bioactive IL-15 is produced in the body as a heterodimeric cytokine, comprising the IL-15 and IL-15 receptor alpha chains (hetIL-15). Several preclinical models support the antitumor activity of hetIL-15 promoting its application in clinical trials.Methods The antitumor activity of hetIL-15 produced from mammalian cells was tested in mouse tumor models (MC38 colon carcinoma and TC-1 epithelial carcinoma). The functional diversity of the immune infiltrate and the cytokine/chemokine network within the tumor was evaluated by flow cytometry, multicolor immunohistochemistry (IHC), gene expression profiling by Nanostring Technologies, and protein analysis by electrochemiluminescence and ELISA assays.Results hetIL-15 treatment resulted in delayed primary tumor growth. Increased NK and CD8+ T cell tumoral infiltration with an increased CD8+/Treg ratio were found by flow cytometry and IHC in hetIL-15 treated animals. Intratumoral NK and CD8+ T cells showed activation features with enhanced interferon-γ (IFN-γ) production, proliferation (Ki67+), cytotoxic potential (Granzyme B+) and expression of the survival factor Bcl-2. Transcriptomics and proteomics analyses revealed complex effects on the tumor microenvironment triggered by hetIL-15 therapy, including increased levels of IFN-γ and XCL1 with intratumoral accumulation of XCR1+IRF8+CD103+ conventional type 1 dendritic cells (cDC1). Concomitantly, the production of the chemokines CXCL9 and CXCL10 by tumor-localized myeloid cells, including cDC1, was boosted by hetIL-15 in an IFN-γ-dependent manner. An increased frequency of circulating CXCR3+ NK and CD8+ T cells was found, suggesting their ability to migrate toward the tumors following the CXCL9 and CXCL10 chemokine gradient.Conclusions Our results show that hetIL-15 administration enhances T cell entry into tumors, increasing the success rate of immunotherapy interventions. Our study further supports the incorporation of hetIL-15 in tumor immunotherapy approaches to promote the development of antitumor responses by favoring effector over regulatory cells and by promoting lymphocyte and DC localization into tumors through the modification of the tumor chemokine and cytokine milieu.https://jitc.bmj.com/content/8/1/e000599.full |
| spellingShingle | Bernard A Fox Cristina Bergamaschi George N Pavlakis Antonio Valentin Jenifer Bear Barbara K Felber Shawn M Jensen Hrishikesh Pandit Bethany A Nagy Dimitris Stellas Maggie Cam Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10 Journal for ImmunoTherapy of Cancer |
| title | Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10 |
| title_full | Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10 |
| title_fullStr | Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10 |
| title_full_unstemmed | Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10 |
| title_short | Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10 |
| title_sort | heterodimeric il 15 delays tumor growth and promotes intratumoral ctl and dendritic cell accumulation by a cytokine network involving xcl1 ifn γ cxcl9 and cxcl10 |
| url | https://jitc.bmj.com/content/8/1/e000599.full |
| work_keys_str_mv | AT bernardafox heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT cristinabergamaschi heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT georgenpavlakis heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT antoniovalentin heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT jeniferbear heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT barbarakfelber heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT shawnmjensen heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT hrishikeshpandit heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT bethanyanagy heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT dimitrisstellas heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 AT maggiecam heterodimericil15delaystumorgrowthandpromotesintratumoralctlanddendriticcellaccumulationbyacytokinenetworkinvolvingxcl1ifngcxcl9andcxcl10 |